A Study of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Metastatic Colorectal Cancer

NCT ID: NCT03356158

Last Updated: 2018-09-17

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 21 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-11-15
• Study Completion Date: 2018-11-30

Brief Summary

This is an open-label, parallel designed study to assess the pharmacokinetics, safety and tolerability of the single-dose and multi-dose of a recombinant anti-EGFR monoclonal antibody (CPGJ602) in patients with at least one prior chemical regimen failed metastatic colorectal cancer. The immunogenicity and preliminary efficacy of CPGJ602 will also be assessed. The study includes 3 parts: part 1: after a single dose of CPGJ602 or cetuximab (the active comparator), the patients will be observed for 4 weeks; part 2: CPGJ602 or cetuximab will be administered to the patients once a week for 5 weeks; part 3: CPGJ602 will be administered to the patients once a week until the patient's death or the withdrawal decision of the patient and/or investigator.

Detailed Description

OBJECTIVES:

Primary:

To assess the pharmacokinetics, safety and tolerability of the single-dose and multi-dose of CPGJ602 administered by intravenous infusion.

Secondary:

To assess the immunogenicity and anti-tumor activity of CPGJ602, compare the pharmacokinetics and immunogenicity between CPGJ602 and the active comparator, cetuximab, and to provide scientific basis for the subsequent phase 2/3 clinical trials.

OUTLINE:

This is an open-label, parallel designed study in patients with at least one prior chemical regimen failed metastatic colorectal cancer. The study can be divided into 3 parts:

Part 1: Single-dose Part

• Arm A: CPGJ602, IV over 2 hours, 100 mg/m2 X 1;
• Arm B: CPGJ602, IV over 2 hours, 400 mg/m2 X 1;
• Arm C: Cetuximab, IV over 2 hours, 400 mg/m2 X 1.

Part 2: Multi-dose Part

The subjects from arm A in Part 1 will be randomized into arm B or C.

• Arm B: CPGJ602, IV, QW, 400 mg/m2 X 1, over 2 hours, followed by 250mg/m2 X4, over 1 hour for each time;
• Arm C: Cetuximab, IV, QW, 400 mg/m2 X 1, over 2 hours, followed by 250mg/m2 X4, over 1 hour for each time. The completion of Day 63 Visit (the visit on the 7th day after the 5th dose in Part 2) can be considered as the completion of the study.

Part 3 (Follow-up Part)

CPGJ602, IV over 1 hour, QW, 250mg/m2, until the patient's death or the withdrawal decision of the patient and/or investigator.

Conditions

Metastatic Colorectal Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

CPGJ 602 low dose

Part 1: CPGJ602, IV over 2 hours, 100 mg/m2 X 1;

Group Type: EXPERIMENTAL

CPGJ602

Intervention Type: BIOLOGICAL

Injection, q.w., 20 mg: 100 ml

CPGJ 602 normal dose

Part 1: CPGJ602, IV over 2 hours, 400 mg/m2 X 1; Part 2: CPGJ602, IV, QW, 400 mg/m2 X 1, over 2 hours, followed by 250mg/m2 X4, over 1 hour for each time;

Group Type: EXPERIMENTAL

CPGJ602

Intervention Type: BIOLOGICAL

Injection, q.w., 20 mg: 100 ml

Cetuximab normal dose

Part 1: Cetuximab, IV over 2 hours, 400 mg/m2 X 1. Part 2: Cetuximab, IV, QW, 400 mg/m2 X 1, over 2 hours, followed by 250mg/m2 X4, over 1 hour for each time.

Group Type: ACTIVE_COMPARATOR

Cetuximab

Intervention Type: BIOLOGICAL

Injection, q.w., 20 mg: 100 ml

Interventions

CPGJ602

Injection, q.w., 20 mg: 100 ml

Intervention Type: BIOLOGICAL

Cetuximab

Injection, q.w., 20 mg: 100 ml

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. 18-70 years old, male or female.

2. Histologically or cytologically confirmed metastatic CRC, and have failed (disease progression or intolerance) at least one prior chemical regimen containing oxaliplatin, irinotecan or 5-FU, etc.

3. ECOG performance status 0 or 1.

4. Estimated life expectancy ≥ 3 months.

5. RAS (including K-ras and N-ras) wide type status.

6. Adequate bone marrow, hepatic and renal functions. Hematopoietic:

Leukocytes (WBC)>4.0×109/L or Absolute Neutrophil Count (ANC)> 1.5×109/L, Platelet Count (PLT)>80×109/L, Hemoglobin (Hb)>90g/ L; Hepatic: Total Bilirubin (T-Bil)≤1.5×ULT (Upper Limit of Normal), Alanine Transaminase (ALT)/ Aspartate Transaminase (AST)≤2.5×ULT or ≤5×ULT in case of liver metastases; Renal: Blood Urea Nitrogen (BUN)≤1.5×ULT, Serum Creatinine (Cr) ≤ 1.5×ULT.

7. At least one measurable disease based on RECIST criteria (v 1.1).

8. Signed informed consent on a voluntary basis at screening, and no geographical condition that would preclude the study compliance.

Exclusion Criteria

1. Less than 28 days since prior chemotherapy, radiotherapy or surgery (diagnosis biopsy is allowed).

2. Previous epidermal growth factor receptor (EGFR) targeted therapies (including monoclonal antibody, tyrosine kinase inhibitor [TKI] and other EGFR targeted therapies, such as cetuximab, nimotuzumab, panitumumab, gefitinib, erlotinib, and icotinib, etc.

3. Known hypersensitivity to study drugs or any of the excipients.

4. Known or clinical suspected brain metastases and/or disease of meninges.

5. Clinically significant cardiovascular or cerebrovascular dis ease, history of myocardial infarction (MI) in the latest 6 months, or high-risk of uncontrolled cardiac arrhythmias.

6. History of acute or sub-acute intestinal obstruction, or of inflammatory bowel disease.

7. A serious and uncontrolled concomitant disease which, in the investigator's opinion, rules out the patient's participation in the study, such as history of malignancies other than CRC (with the exception of: curatively treated carcinoma of the skin [except for melanoma]; cured cervical cancer or basal cell skin cancer, ductal carcinoma in situ [DICS], endometrial carcinoma [stage I grade 1]; and other solid tumors including lymphoma without bone marrow infiltration for which the patient has been disease-free for 5 years), uncontrolled hypertension, diabetes mellitus (DM), peripheral neuropathy, and infectious diseases (including viral, bacterial and parasitic infections), etc.

8. Pregnancy or lactation, or a fertility plan during the participation in this study.

9. No more than 4 weeks or no more than 5 times of t1/2 since prior investigational agents.

10. Other situations that impede the patient's participation in the study at the discretion of the investigator.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jianming Xu, Doctor

Role: PRINCIPAL_INVESTIGATOR

the Afflicated Hospital of Academy of Military Medical Sciences

Locations

Sir Run Run Shaw Hospital

Hangzhou, Zhejiang, China

Site Status: RECRUITING

Countries

China

Central Contacts

Quanrui Wu, Master

Role: CONTACT

wuquanrui@3sbio.com

13601126093

Facility Contacts

Hongming Pan, Doctor

Role: primary

shonco@sina.cn

0571-86006922

Other Identifiers

CPGJ602-001

Identifier Type: -

Identifier Source: org_study_id